Molecular therapy for Metabolic diseases: TAp63 decreases blood pressure and inhibits congestive heart failure via up regulation of AMPKα2, 26/March/2015, 22.20

Expose yourself to optimal Sunlight to live longer: Nitric oxide (endogenous) inhibits senescence and extends life span by down regulating the expression of adenylate cyclase 5 (ADCY5), 25/March/2014, 22.10
March 25, 2015
MiRNA-based therapy for Fibrosis: Endothelin-1 suppresses TGFβ-dependent extracellular matrix accumulation and fibrosis via up regulation of its target gene, 25/March/2015, 22.28
March 25, 2015
Show all

Significance: This study suggests, for the first time, that TAp63, by increasing the expression of its target gene, it may increase the expression of AMPKα2. Thereby, it may: (1) decrease blood pressure;  and (2) congestive heart failure. Thus, pharmacological formulations encompassing “TAp63 activators may be used to treat patients suffering from metabolic diseases, such as high blood pressure and congestive heart failure.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan,  Molecular therapy for Metabolic diseases: TAp63 decreases blood pressure and inhibits congestive heart failure via up  regulation of  AMPKα2, 26/March/2015, 22.20,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Undisclosed information: How TAp63 decreases blood pressure and inhibits congestive heart failure

Comments are closed.